Pharma Securities Fraud Worries Reduced In Supreme Court Omnicare Ruling
This article was originally published in The Tan Sheet
Executive Summary
High court finds that a corporation’s statement of opinion is not actionable unless company did not sincerely believe it; ruling makes it harder for plaintiffs to file stock fraud claims.
You may also be interested in...
Securities Fraud Class Action Suits Could Grow After Amgen’s Supreme Court Loss
Supreme Court rules 6-3 that plaintiffs do not need to prove that a company’s misrepresentations were material at the class certification stage; investors allege Amgen misrepresented the safety of Aranesp and Epogen.
Supreme Court's Matrixx Decision Expands Firms' Disclosure Burden
The Supreme Court's decision in a complaint shareholders brought against Matrixx Initiatives lowers the threshold for when firms need to disclose information, but also aims to prevent an "avalanche of trivial information."
Supreme Court Lets Vioxx Securities Suit Against Merck Stand
The top U.S. court clarifies when the statute of limitations for filing suit begins to run and specifies that intent to deceive is crucial in determining if a violation occurred.